
Technical Report No. 54 Implementation of Quality Risk Management For Pharmaceutical and Biotechnology Manufacturing Operations



Paradigm Change in Manufacturing Operations[™]



2012

PDA PCMO[™] Technical Report 54: Implementation of Quality Risk Management for Commercial and Biotech Manufacturing Operations Task Force Members

Authors

Emabelle Ramnarine, Task Force Leader, Genentech

Jeffrey L. Hartman, Co-Leader, Merck

Thomas Genova, Ph.D., Johnson & Johnson

Laura Huffman, United States Food and Drug Administration

Kathy Lee, United States Food and Drug Administration

Michael A. Long, Ph.D., ConcordiaValSource

Kevin O'Donnell, Ph.D., Irish Medicines Board

Jayesh Patel, F. Hoffmann-La Roche Inc.

Siegfried Schmitt,* Ph.D., PAREXEL Consulting

Rebecca Spohn, Amgen Inc.

Edward C. Tidswell, Ph.D., Baxter Healthcare Corporation

Robert P. Tomaselli, Johnson & Johnson SPT

Anthony C. Warchut, PAREXEL Consulting

Other Contributors

James Agalloco, Agalloco & Associates, Inc.

James E. Akers, Akers, Kennedy and Associates

Kristen Anderson, United States Food and Drug Administration

Veronique D. Davoust, Ph.D., Pfizer

Lance D. Goodreau, New England BioLabs

Ghada Haddad, Genentech

William Harclerode, Forest Labs

Kristin Murray, Pfizer

Stephen Reich, Pfizer

* PDA and the Task Force wants to thank Siegfried Schmitt for spending a considerable amount of time volunteering as the copy editor for this Technical Report. His effort resulted in a well-edited document and saved PDA resources it would normally have committed to a professional copy editor.

This technical report was developed as part of PDA's Paradigm Change in Manufacturing Operations (PCMO) project. The content and views expressed in this Technical Report are the result of a consensus achieved by the Task Force and are not necessarily views of the organizations they represent.

Implementation of Quality Risk Management For Pharmaceutical and Biotechnology Manufacturing Operations

PCMO[™] Technical Report No. 54

ISBN: 978-0-939459-38-4 © 2012 Parenteral Drug Association, Inc. All rights reserved.



Paradigm Change in Manufacturing Operations[™]

Paradigm Change in Manufacturing Operations (PCMO[™])

PDA launched the project activities related to the PCMO program in December 2008 to help implement the scientific application of the ICH Q8, Q9 and Q10 series. The PDA Board of Directors approved this program in cooperation with the Regulatory Affairs and Quality Advisory Board, and the Biotechnology Advisory Board and Science Advisory Board of PDA.


Although there are a number of acceptable pathways to address this concept, the PCMO program follows and covers the drug product lifecycle, employing the strategic theme of process robustness within the framework of the manufacturing operations. This project focuses on Pharmaceutical Quality Systems as an enabler of Quality Risk Management and Knowledge Management.

Using the Parenteral Drug Association's (PDA) membership expertise, the goal of the Paradigm Change in Manufacturing Operations Project is to drive the establishment of 'best practice' documents and /or training events in order to assist pharmaceutical manufacturers of Investigational Medicinal Products (IMPs) and commercial products in implementing the ICH guidelines on Pharmaceutical Development (ICH Q8, Q11), Quality Risk Management (ICH Q9) and Pharmaceutical Quality Systems (ICH Q10).

The PCMO program facilitates communication among the experts from industry, university and regulators as well as experts from the respective ICH Expert Working Groups and Implementation Working Group. PCMO task force members also contribute to PDA conferences and workshops on the subject.

PCMO follows the product lifecycle concept and has the following strategic intent:

- Enable an innovative environment for continual improvement of products and systems
- Integrate science and technology into manufacturing practice
- Enhance manufacturing process robustness, risk based decision making and knowledge management
- Foster communication among industry and regulatory authorities



The Product Life Cycle



For more information, including the PCMO Dossier, and to get involved, go to www.pda.org/pcmo

Table of Contents

5.0

1.0	Introduction1	
	1.1 Purpose and Scope2	
2.0	Glossary of Terms3	
3.0	General Principles On Quality Risk Management Application7	
	3.1 When, Where, and How to Apply Quality Risk	
	Management7 3.1.1 Quality Risk Management Application	
	During Pharmaceutical Development7	
	3.1.2 Quality Risk Management Application	
	during Technology Transfer	
	During Commercial Manufacturing	
	3.1.4 Quality Risk Management Application	
	During Product Discontinuation	
	3.2 Proactive and Reactive Application of Quality Risk Management	
	3.3 Formality of the Quality Risk	
	Management Process9	
	3.4 Establishing a Quality Risk	
	Management Policy	
	3.6 Understanding the Organization and	
	How it Contextualizes Risk	
	3.7 Integration into Organizational Processes 11	
	3.8 Establishing Communication and	
	Reporting Mechanisms	
	3.10 Heuristics and Biases in Quality Risk	
	Management13	
4.0	Implementation Of The Quality Risk Management Process16	
	4.1 Initiating a Quality Risk Management Process16	
	4.2 Risk Assessment16	
	4.2.1 Execution of Risk Assessments	
	4.2.2 Risk Identification	

4.2.3	Risk Analysis
4.2.4	Risk Evaluation
	Supporting Tools
4.3 Risl	k Control
4.3.1	Risk Reduction23
	Risk Acceptance24
4.4 Out	put/Result of the Quality
Risl	k Management Process
4.4.1	Risk Register
4.5 Risl	k Review
	Event-Based Reviews
	.1.1 Deviations or Non-Conformances 26
4.5	.1.2 Product Complaints, Returns,
	or Patient Safety Related Events 26
4.5	1.3 Data Trends
4.5	.1.4 Change Control
4.5	.1.5 Audits and Inspections
4.5.2	Scheduled Reviews 27
4.6 Risl	k Communication27
4.6.1	Essential Elements of
	Risk Communication28
4.6.2	Difficulties with Risk Communication 30
	Use Quality Risk Management
	Enabler
	VI Application During Process
	dation Lifecycle31
5.1.1	
	Stage 1 Process Design
5.1.2	
	Stage 2 Process Qualification
5.1.3	
	Sterilization and Cleaning Validation 33
5.1.4	
	Stage 3 Continued Process Verification 34
	M Application during Facilities, Manufacturing
	Control Systems Lifecycle
5.2.1	
5.2.2	Quality Risk Management Application
	to System Qualification Activities

5.2.3	QRM Application to Facility and Equipment Operation, Maintenance and Continual Improvement				
5.2.4	Facility and Equipment Design: Dedicated				
	Versus Multi-Product Facilities				
5.3 Qua	lity Risk Management Application				
Dur	ing Technology Transfer				
5.4 Quality Risk Management Application in					
Ma	terials Management 41				
5.4.1	Supplier Selection and Management 41				
5.4.2	Risk Control for Suppliers43				
5.4.3	Quality Agreements 45				

5.5 Quality Risk Management Application	
for Contract Services	46
5.5.1 Supplier Selection, Initiation and Technology Transfer	46
5.5.2 Routine Oversight of Supplier	47
5.5.3 Continual Improvement	48
5.5.4 Supplier Decommissioning	48
5.6 Knowledge Management	
6.0 Conclusions	50
7.0 References	51

FIGURES AND TABLES INDEX

Figure 1-1	Example of a Maturity Model for QRM 2	
Figure 3.1-1	Product Lifecycle7	
Figure 3.3-1	Rigor and Formality of QRM Approaches 9	
Figure 3.3-2	Rigor and Formality Spectrum for QRM Activities	
Table 3.7-1	Risk Management Maturity Level 12	
Table 3.10-1	Strategies to Manage Common Perception Biases15	
Figure 4.2-1	Identifying the Level of Rigor for a Risk Assessment	
Table 4.2-1	Comparison of Common Risk Management Tools19	
Figure 4.2.4-1 Classifications of Risks		
Table 4.6.1-1	Summary of Essential Information Conveyed to Ensure an Effective and Sustainable QRM Program	

Figure 5.2.1-1	Systems Lifecycle35
Figure 5.2.2-1	Approach for QRM Application to Determine System Testing Requirements37
Figure 5.2.3-1	QRM Application during Operation and Maintenance Activities
Figure 5.4.1-1	Supplier Assessment and Qualification Lifecycle
Table 5.4.2.1	Example of Risk Management Application to Determine Supplier Audit Frequency44
Figure 5.5-1	Lifecycle for Control of Contract Manufacturing Organizations46
Table 5.5.2-1	Example of QRM Application to Ensure Sufficient CMO Oversight 47